Filed June 10, 2024

Serial No. 98592556

Examining Attorney KATHERINE AILEEN MAHONEY

Class Oligonucleotide compounds being a component in pharmaceutical preparations for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; RNA compounds being a component in pharmaceutical preparations for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; RNA therapeutic agents for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; Nucleic acid therapeutic agents for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; Oligonucleotide compounds being a component in pharmaceutical preparations for use in RNA editing for treating genetic diseases; Oligonucleotide compounds being a component in pharmaceutical preparations for use in base editing for treating genetic diseases; Oligonucleotide compounds being a component in pharmaceutical preparations for use as RNA therapeutic for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; Oligonucleotide compounds being a component in pharmaceutical preparations for treating genetic diseases that facilitate the editing of RNA base; Pharmaceuticals, medicines, biologics, biotherapeutics, biosimilars and therapeutics, namely, nucleic acid therapeutic agents for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; pharmaceuticals, namely, bio-pharmaceutical preparations for the treatment of rare diseases; 005; 006; 018; 044; 046; 051; 052; 100; 103; 106

Case Type Trademark Service mark